New Investment in BRAINBox Solutions To Support Commercialization Of Test, Clinical Study 

BRAINBox Solutions, which is focused on creating a diagnostic/prognostic test for traumatic brain injury (TBI) concussion, gained investment financing from Genoa Ventures and others to support its U.S. regulatory clearance and initial commercialization efforts. Investment totals were not disclosed.;;

BRAINBox was founded in 2018. In 2019, the FDA granted the company’s BRAINBox TBI test for adults Breakthrough Device designation. ;

The company’s completed 2019 HeadSMART II trial to support FDA clearance in adults enrolled 2,000 subjects. BRAINBox has presented clinical data from this trial at several medical meetings in recent months. ;

The . . .